Clik here to view.
CANbridge Life Sciences Raises $10 Million in Series A Round Led by Qiming...
BEIJING CANbridge Life Sciences, a biopharmaceutical company focused on developing Western drug candidates in China and North Asia, announced that it has raised $10 million in a Series A round from...
View ArticleClik here to view.
武田研究中的用于复发或难治全身性轻链淀粉样变的口服蛋白酶体抑制剂Ixazomib被美国FDA认定为突破性治疗药物
马萨诸塞州坎布里奇和日本大阪 (美国商业资讯) –武田药品工业株式会社(TSE:4502)今天宣布，该公司研究中的用于治疗复发或难治全身性轻链(AL)淀粉样变的口服蛋白酶体抑制剂ixazomib (MLN9708) 被美国食品药品监督管理局(FDA)认定为突破性治疗药物。这是首个被认定为突破性治疗药物的蛋白酶体抑制剂和用于AL淀粉样变的研究药物。...
View ArticleClik here to view.
再発性／難治性の全身性軽鎖アミロイドーシスの治療で、武田薬品の経口治験薬となるプロテアソーム阻害薬ixazomibが米FDAから画期的新薬の指定を受ける
米マサチューセッツ州ケンブリッジ & 大阪 — （ビジネスワイヤ） —...
View ArticleClik here to view.
Elekta Ltd and Medical Intelligence Medizintechnik GmbH defend claims by...
CRAWLEY, United Kingdom Regulatory News: humediQ GmbH has initiated legal proceedings against two companies in the Elekta (STO:EKTAB) (EKTA-B.ST) group. The dispute relates to an agreement from...
View ArticleClik here to view.
Biogen Idec to Present Data from Hematology Programs, Including ELOCTATE™ and...
CAMBRIDGE, Mass. Biogen Idec (NASDAQ: BIIB) will present data supporting its approved hemophilia therapies at the 56th Annual Meeting of the American Society of Hematology (ASH) taking place in San...
View ArticleClik here to view.
8th Annual OneMedForum San Francisco Expands Its China Forum into Partnering...
NEW YORK OneMedForum announced today that its 8th annual OneMedForum conference, to be held at the San Francisco Marriott Marquis, Jan. 12-13, 2015, will expand its annual China Forum event at the...
View ArticleClik here to view.
Cytori Expects New Japan Laws to Boost Adoption of Cytori Cell Therapy
SAN DIEGO Cytori Therapeutics, Inc. (NASDAQ: CYTX) today confirmed that two Japanese regenerative medicine laws, which went into effect on November 25, 2014, remove regulatory uncertainties and...
View ArticleClik here to view.
St. Luke’s Medical Center-Global City Trusts UpToDate to Support Exceptional...
WALTHAM, Mass. Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, announced today that St. Luke’s Medical Center-Global City is among the...
View ArticleClik here to view.
テラヴェクティスが自社レンチウイルスベクター技術の知的財産権をさらに強化
パリ （ビジネスワイヤ） — 完全統合型の創薬・臨床開発バイオテクノロジーを手掛ける企業として治療用ワクチンと免疫療法の開発に傾注するテラヴェクティスは、最初の申請（ウェブサイト）からわずか2年後に欧州特許「Lentiviral Vectors Containing an MHC Class I...
View ArticleClik here to view.
昆泰连续3年荣获SCRIP最佳合同研究组织奖
北卡罗莱纳州研究三角园区 (美国商业资讯) – 昆泰今天宣布，该公司连续3年获得每年一次的SCRIP “最佳合同研究组织”奖。这是5年来该公司第四次获得此类奖。SCRIP奖表彰生物制药业的翘楚，由生命科学领域的12位专家组成的独立评委进行评审。 IBI Pharma News & Datamonitor Healthcare全球内容总监Mike...
View ArticleClik here to view.
Takeda Announces Formalization of Takeda Oncology to Enhance Discovery,...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced its global oncology business unit, headquartered in Cambridge, MA, will be called Takeda...
View ArticleClik here to view.
Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from...
SAN FRANCISCO Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today reported data demonstrating that Hodgkin lymphoma (HL) patients at risk of relapse...
View ArticleClik here to view.
U.S. FDA Approves the Labeling Update of Abilify Maintena® (Aripiprazole) for...
TOKYO & VALBY, Denmark Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify...
View ArticleClik here to view.
「ABILIFY MAINTENA®」（エビリファイ メンテナ）米国で統合失調症の急性期試験データを添付文書に追加
東京とコペンハーゲン （ビジネスワイヤ） –大塚製薬株式会社（本社：東京都、代表取締役社長：岩本太郎、以下「大塚製薬」）とH.ルンドベックA/S（本社：デンマーク、コペンハーゲン、取締役会議長：ホーカン ビョークルン、以下「ルンドベック社」）は、急性期統合失調症患者さんを対象とした臨床試験の結果により、持続性懸濁注射剤である「Abilify Maintena®」（エビリファイ...
View ArticleClik here to view.
Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS®...
SAN FRANCISCO Seattle Genetics, Inc. (Nasdaq: SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced four-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin)...
View ArticleClik here to view.
Generon Presents the Global Phase II Study Results for F-627 (benegrastim) at...
SHANGHAI Generon (Shanghai) Corporation, a leading biopharmaceutical company in China, today announced the presentation of the global Phase II study results for F-627 (benegrastim) at the American...
View ArticleClik here to view.
Integra Holdings Closes $3 Million Investment from Guangxi Wuzhou...
JERUSALEM Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, announced today that it has received US $3 million...
View ArticleClik here to view.
昆泰啟動已上市產品維護服務，以便有效管理成熟產品
北卡羅萊納州三角研究園區 (美國商業資訊) – 昆泰今天發布了一項新服務，該服務將該公司業界領先的藥物警戒、法規文獻/說明書維護、收益風險管理和分析專業技能匯總成一套整合的解決方案。該解決方案將幫助生物製藥公司有效管理維護他們已上市產品陣容的授權所需的全部活動。...
View ArticleClik here to view.
Clik here to view.
武田宣布成立武田肿瘤部，以加强突破性抗癌药的发现、开发和全球商业化
马萨诸塞州剑桥和日本大阪 (美国商业资讯)–武田药品工业株式会社(TSE:4502)今天宣布，其总部位于马萨诸塞州剑桥的全球肿瘤业务部将命名为武田肿瘤部(Takeda...
View Article